InnocsAI Deal History & Licensing Activity
InnocsAI is a life sciences. Over the past three years, InnocsAI has been involved in 3 licensing and acquisition transactions, with a primary focus on CAR-T (6 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
CAR-T
Focus Area
Mega Deals
InnocsAI Recent Deal Activity
Licensing, acquisition, and partnership transactions involving InnocsAI in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CAR-T oncology platform | Liminatus Pharma | CAR-T | Unknown | acquisition | May 2026 |
| InnocsAI CAR-T platform | Liminatus | CAR-T | Unknown | acquisition | May 2026 |
| Liminatus Pharma CAR-T program | Liminatus Pharma | CAR-T | Unknown | acquisition | May 2026 |
InnocsAI Pipeline Focus
Therapeutic areas and modalities where InnocsAI is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches InnocsAI's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About InnocsAI Licensing & Deal Activity
InnocsAI is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, InnocsAI ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for InnocsAI include Mega Deals (6 deals and trials). In terms of modality, InnocsAI has shown particular interest in car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for InnocsAI and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against InnocsAI's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.